• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
VHL
Click for more information
7.69% 14.0¢

VIRAX HOLDINGS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
VHL s708A Notice & Appendix 3B11/12/14
VHL Prescient completes acquisition of AKTivate TherapeuticsPRICE SENSITIVE11/12/14
VHL Completion of Capital Consolidation05/12/14
VHL Initial Director's Interest Notices03/12/14
VHL Final Director's Interest Notices03/12/14
VHL Change of Company Name02/12/14
VHL Results of Meeting - 201428/11/14
VHL Results of Meeting - 2013 meeting28/11/14
VHL Results of Meeting - 2012 meeting28/11/14
VHL VHL boosts leadership with key chair and board appointments28/11/14
VHL Virax Shareholder Newsletter07/11/14
VHL Annual Report to shareholders03/11/14
VHL Appendix 4C - quarterlyPRICE SENSITIVE03/11/14
VHL ASX Grants Waiver - Listing Rule 10.13.331/10/14
VHL Company overview brochure30/10/14
VHL Notice of AGM, including Independent Experts Report30/10/14
VHL Notice of Annual General Meeting/Proxy Form29/10/14
VHL Notices of AGM in relation to the 2012 and 2013 years29/10/14
VHL Roadshow Presentation28/10/14
VHL Video Presentation with Managing Director17/10/14
VHL VHL TO ACQUIRE DEEP AKT INHIBITOR PORTFOLIOPRICE SENSITIVE17/10/14
VHL Trading Halt Request15/10/14
VHL Trading HaltPRICE SENSITIVE15/10/14
VHL Multiple Myeloma Authority Joins Scientific Advisory Board23/09/14
VHL FDA IND Re-Activation Request for Phase Ib/II TrialPRICE SENSITIVE09/09/14
VHL Virax Holdings Appendix 4E and 2014 Financial ReportPRICE SENSITIVE01/09/14
VHL Appendix 4C - quarterlyPRICE SENSITIVE31/07/14
VHL Investor Roadshow Presentation23/07/14
VHL Cancer Authority to help Steer US Breast Cancer Progam21/07/14
VHL Initial Director's Interest Notice24/06/14
VHL VHL appoints Ground Zero Pharmaceuticals23/06/14
VHL New MD to Present at International Life Sciences Showcase16/06/14
VHLInitial Director's Interest Notice06/06/14
VHLVHL completes Pathway acquisiton, appoints new directorPRICE SENSITIVE30/05/14
VHLAppendix 3B30/05/14
VHLAppendix 3B20/05/14
VHLAppointment of Managing Director to Drive Cancer ProgramsPRICE SENSITIVE15/05/14
VHLAppendix 3B15/05/14
VHLDisclosure DocumentPRICE SENSITIVE14/05/14
VHLCapital Raising UpdatePRICE SENSITIVE09/05/14
VHLResults of Meeting09/05/14
VHLChairman's Address at General Meeting09/05/14
VHLInvestor Newsletter06/05/14
VHLVirax Option to Acquire Exclusive Worldwide LicencePRICE SENSITIVE05/05/14
VHLTrading HaltPRICE SENSITIVE01/05/14
VHLAppendix 4C - quarterlyPRICE SENSITIVE30/04/14
VHLAppointment of Gene Tech expert to further develop assets29/04/14
VHLCo-X-Gene Development PipelinePRICE SENSITIVE24/04/14
VHLNotice of General Meeting/Proxy Form08/04/14
VHLASX Grants Waivers - Listing Rule 7.3.203/04/14
VHLAppendix 3B27/03/14
VHLVirax secures $3 million placementPRICE SENSITIVE25/03/14
VHLTrading HaltPRICE SENSITIVE21/03/14
VHLInvestor presentation17/03/14
VHLVirax to acquire advanced cancer platform from Yale UniPRICE SENSITIVE17/03/14
VHLTrading HaltPRICE SENSITIVE14/03/14
VHLHalf Yearly Report and AccountsPRICE SENSITIVE28/02/14
VHLIntellectual Property Report UpdatePRICE SENSITIVE19/02/14
VHLAppendix 3B18/02/14
VHLResponse to ASX Aware LetterPRICE SENSITIVE12/02/14
VHLTransgene Announces Topline Preliminary ResultsPRICE SENSITIVE07/02/14
VHLAppendix 3B11/12/13
VHLCompany Update05/12/13
VHLReinstatement to Offical Quotation19/11/13
VHLResponse to ASX Appendix 3Z Query19/11/13
VHLASX Circular - Reinstatement to Official Quotation18/11/13
VHLReinstatement to Official Quotation - 19 November 2013PRICE SENSITIVE18/11/13
VHLPre-quotation disclosures14/11/13
VHLRetirement of Deed Administrator14/11/13
VHLAnnual Report for the Year Ended 30 June 201314/11/13
VHLHalf Yearly Report for the period ended 31 December 201214/11/13
VHLAnnual Report for the Year Ended 30 June 201214/11/13
VHLAdministrator/Receiver ??? Appointed/Removed13/11/13
VHLChange of Director's Interest Notices29/10/13
VHLFinal Director's Interest Notices29/10/13
VHLCompletion of Recapitalisation Proposal25/10/13
VHLCompany Secretary Appointment/Resignation21/10/13
VHLChange in substantial holding10/10/13
VHLAppendix 3B25/09/13
VHLProspectus19/09/13
VHLAnnouncement of Updated Constitution03/09/13
VHLHeader Corr: Consolidation process as approved by Sh'holders03/09/13
VHLAnnouncement of New Board/Appendix 3X Notices03/09/13
VHLInternal03/09/13
VHLResults of Meeting02/09/13
VHLDetails of Share Registry address30/07/13
VHLNotice of General Meeting30/07/13
VHLCompany Administration - Other28/02/13
VHLExecution of Deed of Company Arrangement29/10/12
VHLCompany Administration - Other12/10/12
VHLAppointment of Voluntary Administrators 24 August 201224/08/12
VHLConvertible Note Quarterly Report 30 06 201231/07/12
VHLAppendix 3B - 15 June 201215/06/12
VHLRequest for Continuation of Suspension15/06/12
VHLTermination Share Purchase Agreement - 4G Vaccines Pty Ltd15/06/12
VHLCo-X-Gene Sub Licence and TG400114/05/12
VHLConvertible Notes - Quarterly Report 31/3/201230/04/12
VHLNoteholder General Meeting Results - 30 March 201230/03/12
VHLNoteholder Notice of Meeting - 30 March 201215/03/12
VHLAppendix 4D (31 December 2011)14/03/12
VHL s708A Notice & Appendix 3B
11/12/14
VHL Prescient completes acquisition of AKTivate Therapeutics
11/12/14PRICE SENSITIVE
VHL Completion of Capital Consolidation
05/12/14
VHL Initial Director's Interest Notices
03/12/14
VHL Final Director's Interest Notices
03/12/14
VHL Change of Company Name
02/12/14
VHL Results of Meeting - 2014
28/11/14
VHL Results of Meeting - 2013 meeting
28/11/14
VHL Results of Meeting - 2012 meeting
28/11/14
VHL VHL boosts leadership with key chair and board appointments
28/11/14
VHL Virax Shareholder Newsletter
07/11/14
VHL Annual Report to shareholders
03/11/14
VHL Appendix 4C - quarterly
03/11/14PRICE SENSITIVE
VHL ASX Grants Waiver - Listing Rule 10.13.3
31/10/14
VHL Company overview brochure
30/10/14
VHL Notice of AGM, including Independent Experts Report
30/10/14
VHL Notice of Annual General Meeting/Proxy Form
29/10/14
VHL Notices of AGM in relation to the 2012 and 2013 years
29/10/14
VHL Roadshow Presentation
28/10/14
VHL Video Presentation with Managing Director
17/10/14
VHL VHL TO ACQUIRE DEEP AKT INHIBITOR PORTFOLIO
17/10/14PRICE SENSITIVE
VHL Trading Halt Request
15/10/14
VHL Trading Halt
15/10/14PRICE SENSITIVE
VHL Multiple Myeloma Authority Joins Scientific Advisory Board
23/09/14
VHL FDA IND Re-Activation Request for Phase Ib/II Trial
09/09/14PRICE SENSITIVE
VHL Virax Holdings Appendix 4E and 2014 Financial Report
01/09/14PRICE SENSITIVE
VHL Appendix 4C - quarterly
31/07/14PRICE SENSITIVE
VHL Investor Roadshow Presentation
23/07/14
VHL Cancer Authority to help Steer US Breast Cancer Progam
21/07/14
VHL Initial Director's Interest Notice
24/06/14
VHL VHL appoints Ground Zero Pharmaceuticals
23/06/14
VHL New MD to Present at International Life Sciences Showcase
16/06/14
VHLInitial Director's Interest Notice
06/06/14
VHLVHL completes Pathway acquisiton, appoints new director
30/05/14PRICE SENSITIVE
VHLAppendix 3B
30/05/14
VHLAppendix 3B
20/05/14
VHLAppointment of Managing Director to Drive Cancer Programs
15/05/14PRICE SENSITIVE
VHLAppendix 3B
15/05/14
VHLDisclosure Document
14/05/14PRICE SENSITIVE
VHLCapital Raising Update
09/05/14PRICE SENSITIVE
VHLResults of Meeting
09/05/14
VHLChairman's Address at General Meeting
09/05/14
VHLInvestor Newsletter
06/05/14
VHLVirax Option to Acquire Exclusive Worldwide Licence
05/05/14PRICE SENSITIVE
VHLTrading Halt
01/05/14PRICE SENSITIVE
VHLAppendix 4C - quarterly
30/04/14PRICE SENSITIVE
VHLAppointment of Gene Tech expert to further develop assets
29/04/14
VHLCo-X-Gene Development Pipeline
24/04/14PRICE SENSITIVE
VHLNotice of General Meeting/Proxy Form
08/04/14
VHLASX Grants Waivers - Listing Rule 7.3.2
03/04/14
VHLAppendix 3B
27/03/14
VHLVirax secures $3 million placement
25/03/14PRICE SENSITIVE
VHLTrading Halt
21/03/14PRICE SENSITIVE
VHLInvestor presentation
17/03/14
VHLVirax to acquire advanced cancer platform from Yale Uni
17/03/14PRICE SENSITIVE
VHLTrading Halt
14/03/14PRICE SENSITIVE
VHLHalf Yearly Report and Accounts
28/02/14PRICE SENSITIVE
VHLIntellectual Property Report Update
19/02/14PRICE SENSITIVE
VHLAppendix 3B
18/02/14
VHLResponse to ASX Aware Letter
12/02/14PRICE SENSITIVE
VHLTransgene Announces Topline Preliminary Results
07/02/14PRICE SENSITIVE
VHLAppendix 3B
11/12/13
VHLCompany Update
05/12/13
VHLReinstatement to Offical Quotation
19/11/13
VHLResponse to ASX Appendix 3Z Query
19/11/13
VHLASX Circular - Reinstatement to Official Quotation
18/11/13
VHLReinstatement to Official Quotation - 19 November 2013
18/11/13PRICE SENSITIVE
VHLPre-quotation disclosures
14/11/13
VHLRetirement of Deed Administrator
14/11/13
VHLAnnual Report for the Year Ended 30 June 2013
14/11/13
VHLHalf Yearly Report for the period ended 31 December 2012
14/11/13
VHLAnnual Report for the Year Ended 30 June 2012
14/11/13
VHLAdministrator/Receiver ??? Appointed/Removed
13/11/13
VHLChange of Director's Interest Notices
29/10/13
VHLFinal Director's Interest Notices
29/10/13
VHLCompletion of Recapitalisation Proposal
25/10/13
VHLCompany Secretary Appointment/Resignation
21/10/13
VHLChange in substantial holding
10/10/13
VHLAppendix 3B
25/09/13
VHLProspectus
19/09/13
VHLAnnouncement of Updated Constitution
03/09/13
VHLHeader Corr: Consolidation process as approved by Sh'holders
03/09/13
VHLAnnouncement of New Board/Appendix 3X Notices
03/09/13
VHLInternal
03/09/13
VHLResults of Meeting
02/09/13
VHLDetails of Share Registry address
30/07/13
VHLNotice of General Meeting
30/07/13
VHLCompany Administration - Other
28/02/13
VHLExecution of Deed of Company Arrangement
29/10/12
VHLCompany Administration - Other
12/10/12
VHLAppointment of Voluntary Administrators 24 August 2012
24/08/12
VHLConvertible Note Quarterly Report 30 06 2012
31/07/12
VHLAppendix 3B - 15 June 2012
15/06/12
VHLRequest for Continuation of Suspension
15/06/12
VHLTermination Share Purchase Agreement - 4G Vaccines Pty Ltd
15/06/12
VHLCo-X-Gene Sub Licence and TG4001
14/05/12
VHLConvertible Notes - Quarterly Report 31/3/2012
30/04/12
VHLNoteholder General Meeting Results - 30 March 2012
30/03/12
VHLNoteholder Notice of Meeting - 30 March 2012
15/03/12
VHLAppendix 4D (31 December 2011)
14/03/12
refresh Created with Sketch. REFRESH
 

Top Stories

Cyclone signs MOU with Vale for development of Iron Bear play

Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
HotCopper Highlights: Your most watched stocks for Week 46, 2024 What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.